Categories: News

The Heart Failure Society of America Releases Review Examining the Growing Economic Burden of Heart Failure in the United States

ROCKVILLE, Md., Jan. 24, 2022 /PRNewswire/ — Today, the Heart Failure Society of America (HFSA) released a review, Economic Issues in Heart Failure in the United States, in the Journal of Cardiac Failure (JCF). The review examines the growing economic burden of heart failure for patients and the health care system in the United States, providing a summary of evidence for the cost-effectiveness of drugs, devices, diagnostic tests, hospital care, and transitions of care for patients with heart failure.

This review sheds light on the important role of cost-effectiveness and the value of diagnosis and treatment in HF care.

The HFSA Advocacy Committee developed the review to support their advocacy of high value care and to provide a roadmap for maximizing benefits for patients with heart failure within a limited health care budget. It highlights the economic impact of heart failure exploring hospitalization trends, readmission, transitions of care, outpatient trends, disparities, and the impact of the COVID-19 Pandemic.

“Despite remarkable recent advances in the treatment of heart failure, the high cost of care limits delivery of effective care,” said Paul Heidenreich, MD, MS, lead author, Chair of the HFSA Advocacy Committee and Professor and Vice Chair for Quality in the Department of Medicine at Stanford University. “This review pulls together the summary of evidence to allow for decision making that leads to the best results for patients’ health and the healthcare system.”

Economic Issues in Heart Failure in the United States sheds light on the important role of price, cost-effectiveness, and the value of diagnosis and treatment, which HFSA and JCF leadership recognize as critical components of caring for patients with heart failure.

The paper Economic Issues in Heart Failure in the United States was published online in the Journal of Cardiac Failure, the official journal of the Heart Failure Society of America (HFSA) and the Japanese Heart Failure Society (JHFS). It will be published in the March 2022 print issue. It can be accessed via the JCF online or the HFSA Scientific Statements webpage.

Coauthors: Paul A. Heidenreich MD, MS; Gregg C. Fonarow MD; Yekaterina Opsha PharmD BCPS- AQ Cardiology; Alexander T. Sandhu MD; Nancy K. Sweitzer MD, PhD; Haider J. Warraich MD

DOI: https://doi.org/10.1016/j.cardfail.2021.12.017

About the Heart Failure Society of America

The Heart Failure Society of America, Inc. (HFSA) represents the first organized effort by heart failure experts from the Americas to provide a forum for all those interested in heart function, heart failure, and congestive heart failure (CHF) research and patient care. The mission of HFSA is to provide a platform to improve and expand heart failure care through collaboration, education, innovation, research, and advocacy. HFSA members include physicians, scientists, nurses, nurse practitioners, pharmacists, trainees, other healthcare workers and patients. For more information, visit hfsa.org.

About the Journal of Cardiac Failure

The Journal of Cardiac Failure publishes peer-reviewed manuscripts of interest to clinicians and researchers in the field of heart failure and related disciplines. These include original communications of scientific importance and review articles involving clinical research, health services and outcomes research, animal studies, and bench research with potential clinical applications to heart failure. The Journal also publishes manuscripts that report the design of ongoing clinical trials and editorial perspectives that comment on new developments pertinent to the field of heart failure or manuscripts published in other journals.

Media Contact: Laura Poko, 301-798-4493, ext. 226, lpoko@hfsa.org

View original content to download multimedia:https://www.prnewswire.com/news-releases/the-heart-failure-society-of-america-releases-review-examining-the-growing-economic-burden-of-heart-failure-in-the-united-states-301466820.html

SOURCE Heart Failure Society of America

Staff

Recent Posts

Danish start-up Kvantify secures EUR 10 million seed round to unlock quantum computing potential, starting with life sciences

The round is led by Danish VC Dreamcraft, together with biotech investor Lundbeckfonden BioCapital and…

56 mins ago

High-Growth Industries with 25%-30% CAGR Growth Over the Next Five Years

BCC Research Identifies Key Sectors with Substantial Growth Potential, Forecasting Significant Market Expansion Through 2029.…

57 mins ago

Bioz Brings Cutting-Edge AI Citation Widgets to Precision X-Ray, Inc.’s Product Pages

PALO ALTO, CA / ACCESSWIRE / July 3, 2024 / Bioz, Inc., a pioneering AI…

57 mins ago

iZafe Group Receives Confirmed Order of 500 Dosell Units from Ti Medi

STOCKHOLM, SWEDEN / ACCESSWIRE / July 3, 2024 / iZafe Group (STO:IZAFE-B.ST) iZafe Group AB…

57 mins ago

GSK and CureVac to Restructure Collaboration into New Licensing Agreement

GSK acquires full rights to develop, manufacture and commercialize globally mRNA candidate vaccines for influenza…

4 hours ago

CureVac Initiates Strategic Restructuring to Align Resources with Focus on High-Value mRNA Pipeline Opportunities

Strategic restructuring includes a workforce reduction of approximately 30%, re-focusing on research, development, and innovation…

4 hours ago